Paediatric Drugs

, Volume 2, Issue 3, pp 223–238 | Cite as

Analgesics and Breast-Feeding

Safety Considerations
Review Article


The issue of prescription of analgesics during lactation is clinically important but also complex. Most of the information available is based on single dose or short term studies, and for many drugs only a single or a few case reports have been published. As great methodological problems exist in the assessment of possible adverse drug reactions in neonates and infants, there is limited knowledge about the practical impact of the, often very low, concentrations found. Nevertheless, some recommendations can be made.

Breast-feeding during maternal treatment with paracetamol (acetaminophen) should be regarded as being safe. Short term use of nonsteroidal anti-inflammatory drugs seems to be compatible with breast-feeding. For long term treatment, short-acting agents without active metabolites, such as ibuprofen, should possibly be preferred. The use of aspirin (acetylsalicylic acid) in single doses should not pose any significant risks to the suckling infant.

Use of codeine is probably compatible with breast-feeding, although the effects of long term exposure have not been fully elucidated. For propoxyphene, it seems unlikely that the suckling infant will ingest amounts that will cause any detrimental effects during short term treatment. However, it cannot be excluded that significant amounts of the metabolite norpropoxyphene may arise in the suckling infant during long term exposure.

Treatment of the mother with single doses of morphine or pethidine (meperidine) is not expected to cause any risk for the suckling infant. Repeated administration of pethidine, in contrast to morphine, affects the suckling infant negatively. Thus, morphine should be preferred in lactating mothers However, during long term treatment with morphine, the importance of uninterrupted breast-feeding should be assessed on an individual basis against the potential risk of adverse drug effects in the infant. If it is decided to continue breast-feeding the infant should be observed for possible adverse effects.

In general, if treatment of a lactating mother with an analgesic drug is considered necessary, the lowest effective maternal dose should be given. Moreover, infant exposure can be further reduced if breast-feeding is avoided at times of peak drug concentration in milk. As breast milk has considerable nutritional, immunological and other advantages over formula milk, the possible risks to the infant should always, and on an individual basis, be carefully weighed against the benefits of continuing breast-feeding.


Morphine Breast Milk Naproxen Piroxicam Pethidine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Dewey KG, Heinig MJ, Nommsen-Rivers LA. Differences in morbidity between breast-fed and formula-fed infants. J Pediatr 1995; 126: 696–702PubMedCrossRefGoogle Scholar
  2. 2.
    Ford K, Labbok M. Breast-feeding and child health in the United States. J Biosoc Sci 1993; 25: 187–94PubMedCrossRefGoogle Scholar
  3. 3.
    Wright AL, Holberg CJ, Martinez FD, et al. Breast-feeding and lower respiratory tract illness in the first year of life. BMJ 1989; 299: 946–9PubMedCrossRefGoogle Scholar
  4. 4.
    Pisacane A, Graziano L, Mazzarella G, et al. Breast-feeding and urinary tract infection. J Pediatr 1992; 120: 87–9PubMedCrossRefGoogle Scholar
  5. 5.
    Saarinen UM, Kajosaari M, Backman A, et al. Prolonged breastfeeding as prophylaxis for atopic disease. Lancet 1979; II: 163–8CrossRefGoogle Scholar
  6. 6.
    Hahn-Zoric M, Fulconis F, Minoli I, et al. Antibody responses to parenteral and oral vaccines are impaired by conventional and low protein formulas as compared to breast-feeding. Acta Paediatr Scand 1990; 79: 1137–42PubMedCrossRefGoogle Scholar
  7. 7.
    Riordan JM. The cost of not breastfeeding: a commentary. J Hum Lact 1997; 13: 93–7PubMedCrossRefGoogle Scholar
  8. 8.
    Ball TM, Wright AL. Health care costs of formula-feeding in the first year of life. Pediatrics 1999; 103: 870–6PubMedGoogle Scholar
  9. 9.
    Byers T, Graham S, Rzepka T, et al. Lactation and breast cancer: evidence for a negative association in premenopausal women. Am J Epidemiol 1985; 121: 664–74PubMedCrossRefGoogle Scholar
  10. 10.
    Spigset O, Hägg S. Excretion of psychotropic drugs into breast milk. CNS Drugs 1998; 9: 111–34CrossRefGoogle Scholar
  11. 11.
    Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525–38PubMedCrossRefGoogle Scholar
  12. 12.
    Yue QY, Hasselström J, Svensson JO, et al. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparison between extensive and poor metabolisers of debrisoquine. Br J Clin Pharmacol 1991; 31: 635–42PubMedCrossRefGoogle Scholar
  13. 13.
    Bertilsson L. Geographic/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29: 192–209PubMedCrossRefGoogle Scholar
  14. 14.
    Casey C, Hambridge KM. Nutritional aspects of human lactation. In: Neville MC, Neifert MR, editors. Lactation: physiology, nutrition and breast-feeding. New York (NY): Plenum Press, 1983: 199–248Google Scholar
  15. 15.
    Öhman R, Hägg S, Carleborg L, et al. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999; 60: 519–23PubMedCrossRefGoogle Scholar
  16. 16.
    Prentice A, Prentice AM, Whitehead RG. Breast-milk fat concentrations of rural African women: short-term variations within individuals. Br J Nutr 1981; 45: 483–94PubMedCrossRefGoogle Scholar
  17. 17.
    Bennett PN. Drugs and human lactation. 2nd ed. Amsterdam: Elsevier, 1996Google Scholar
  18. 18.
    Wilson JT, Brown DJ, Hinson JL, et al. Pharmacokinetic pitfalls in the estimation of the breast milk/plasma ratio for drugs. Annu Rev Pharmacol Toxicol 1985; 25: 667–89PubMedCrossRefGoogle Scholar
  19. 19.
    Anderson PO. Drugs and breast-feeding. Semin Perinatol 1979; 3: 271–8PubMedGoogle Scholar
  20. 20.
    Gourley GR, Arend RA. β-Glucuronidase and hyperbilirubinaemia in breast-fed and formula-fed babies. Lancet 1986; I: 644–6CrossRefGoogle Scholar
  21. 21.
    Morselli PL. Clinical pharmacokinetics in neonates. Clin Pharmacokinet 1976; 1: 81–9PubMedCrossRefGoogle Scholar
  22. 22.
    Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants. Clin Pharmacokinet 1980; 5: 485–527PubMedCrossRefGoogle Scholar
  23. 23.
    Mammen GJ, editor. Clinical pharmacokinetics: drug data handbook. 2nd ed. Auckland: Adis Press Limited, 1990Google Scholar
  24. 24.
    Kanto J. Risk-benefit assessment of anaesthetic agents in the puerperium. Drug Saf 1991; 6: 285–301PubMedCrossRefGoogle Scholar
  25. 25.
    Rane A. Drug disposition and action in infants and children. In: Yaffe SJ, Aranda JV, editors. Pediatric pharmacology. 2nd ed. Philadelphia (PA): W.B. Saunders, 1992: 10–21Google Scholar
  26. 26.
    Gauntlett IS, Fisher DM, Hertzka RE, et al. Pharmacokinetics of fentanyl in neonatal humans and lambs: effects of age. Anesthesiology 1988; 69: 683–7PubMedCrossRefGoogle Scholar
  27. 27.
    Levy G, Garettson LK. Kinetics of salicylate elimination by newborn infants of mothers who ingested aspirin before delivery. Pediatrics 1974; 53: 201–10PubMedGoogle Scholar
  28. 28.
    Jopkins CS, Underhill S, Booker PD. Pharmacokinetics of paracetamol after cardiac surgery. Arch Dis Child 1990; 65: 971–6CrossRefGoogle Scholar
  29. 29.
    Traeger A, Nöschel H, Zaumseil J. Zur Pharmakokinetik von Indomethazin bei Schwangeren, Kreissenden und deren Neugeborenen. Zentralbl Gynaekol 1973; 95: 635–41Google Scholar
  30. 30.
    Blumer JL, Reed MD. Principles of neonatal pharmacology. In: Yaffe SJ, Aranda JV, editors. Pediatric pharmacology. 2nd ed. Philadelphia (PA): W.B. Saunders, 1992: 164–77Google Scholar
  31. 31.
    Kanto JH. Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations. Drugs 1982; 23: 354–80PubMedCrossRefGoogle Scholar
  32. 32.
    Notarianni LJ, Oldham HG, Bennett PN. Passage of paracetamol into breast milk and its subsequent metabolism by the neonate. Br J Clin Pharmacol 1987; 24: 63–7PubMedCrossRefGoogle Scholar
  33. 33.
    Bitzén P-O, Gustafsson B, Jostell KG, et al. Excretion of paracetamol in human breast milk. Eur J Clin Pharmacol 1981; 20: 123–5PubMedCrossRefGoogle Scholar
  34. 34.
    Berlin Jr CM, Yaffe SJ, Ragni M. Disposition of acetaminophen in milk, saliva, and plasma of lactating women. Pediatr Pharmacol 1980; 1: 135–41Google Scholar
  35. 35.
    Matheson I, Lunde PKM, Notarianni L. Infant rash caused by paracetamol in breast milk? Pediatrics 1985; 76: 651–2PubMedGoogle Scholar
  36. 36.
    Findlay JWA, DeAngelis RL, Kearney MF, et al. Analgesic drugs in milk and plasma. Clin Pharmacol Ther 1981; 29: 625–33PubMedCrossRefGoogle Scholar
  37. 37.
    Ito S, Blajchman A, Stephenson M, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol 1993; 168: 1393–9PubMedGoogle Scholar
  38. 38.
    Kwit NT, Hatcher RA. Excretion of drugs in milk. Am J Dis Child 1935; 49: 900–4Google Scholar
  39. 39.
    Bailey DN, Weibert RT, Naylor AJ, et al. A study of salicylate and caffeine excretion in the breast milk of two nursing mothers. J Anal Toxicol 1982; 6: 64–8PubMedGoogle Scholar
  40. 40.
    Erickson SH, Oppenheim GL. Aspirin in breast milk. J Fam Pract 1979; 8: 189–90PubMedGoogle Scholar
  41. 41.
    Jamali F, Keshavarz E. Salicylate excretion in breast milk. Int J Pharmacol 1981; 8: 285–90CrossRefGoogle Scholar
  42. 42.
    Pütter J, Satravaha P, Stockhausen H. Quantitative Bestimmung der Hauptmetaboliten der Acetylsalizylsäure. Vergleichende Bestimmung in Blut und Milch von Stillenden Frauen. Z Geburtshilfe Perinatol 1974; 178: 135–8Google Scholar
  43. 43.
    Pütter J. Übersicht über die Pharmakokinetik der Acetylsalizylsäure. Med Welt 1976; 27: 1362–5PubMedGoogle Scholar
  44. 44.
    Needs CJ, Brooks PM. Antirheumatic medication during lactation. Br J Rheumatol 1985; 24: 291–7PubMedCrossRefGoogle Scholar
  45. 45.
    Stuart MJ, Gross SJ, Elrad H, et al. Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N Engl J Med 1982; 307: 909–12PubMedCrossRefGoogle Scholar
  46. 46.
    Clark JH, Wilson WG. A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. Clin Pediatr (Phila) 1981; 20: 53–4CrossRefGoogle Scholar
  47. 47.
    Unsworth J, d’Assis Fonseca A, Beswick DT, et al. Serum salicylate levels in a breast fed infant. Ann Rheum Dis 1987; 46: 638–9PubMedCrossRefGoogle Scholar
  48. 48.
    Terragna A, Spirito L. Porpora trombocitopenica in lattante dopo somministrazione di acido acetilsalicilico alla nutrice. Minerva Pediatr 1967; 19: 613–6PubMedGoogle Scholar
  49. 49.
    Butler D. Infantile colic and aspirin [letter]. Med J Aust 1987; 146: 179PubMedGoogle Scholar
  50. 50.
    American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93: 137–50Google Scholar
  51. 51.
    Byron MA. Prescribing in pregnancy: treatment of rheumatic diseases. BMJ 1987; 294: 236–8PubMedCrossRefGoogle Scholar
  52. 52.
    Schoenfeld A, Bar Y, Merlob P, et al. NSAIDs: maternal and fetal considerations. Am J Reprod Immunol 1992; 28: 141–7PubMedGoogle Scholar
  53. 53.
    Berlin CM. Drugs and chemicals: exposure of the nursing mother. Pediatr Clin North Am 1989; 36: 1089–97PubMedGoogle Scholar
  54. 54.
    Anderson PO. Drug use during breast-feeding. Clin Pharm 1991; 10: 594–624PubMedGoogle Scholar
  55. 55.
    Bald R, Bernbeck-Betthäuser EM, Spahn H, et al. Excretion of azapropazone in human breast milk. Eur J Clin Pharmacol 1990; 39: 271–3PubMedCrossRefGoogle Scholar
  56. 56.
    Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988; 35: 244–85PubMedCrossRefGoogle Scholar
  57. 57.
    Zylber-Katz E, Linder N, Granit L, et al. Excretion of dipyrone metabolites in human breast milk. Eur J Clin Pharmacol 1986; 30: 359–61PubMedCrossRefGoogle Scholar
  58. 58.
    Dell HD, Fiedler J. Prüfung der Elimination von Etofenamat in die Milch. Arch Pharm Weinheim 1983; 316: 746–51PubMedCrossRefGoogle Scholar
  59. 59.
    Chiccarelli FS, Eisner HJ, Van Lear GE. Metabolic and pharmacokinetic studies with fenbufen in man. Arzneimittelforschung 1980; 30: 728–35PubMedGoogle Scholar
  60. 60.
    Buchanan RA, Eaton CJ, Koeff ST, et al. The breast milk excretion on flufenamic acid. Curr Ther Res Clin Exp 1969; 11: 533–8PubMedGoogle Scholar
  61. 61.
    Smith IJ, Hinson JL, Johnson VA, et al. Flurbiprofen in postpartum women: plasma and breast milk disposition. J Clin Pharmacol 1989; 29: 174–84PubMedGoogle Scholar
  62. 62.
    Cox SR, Forbes KK. Excretion of flurbiprofen into breast milk. Pharmacotherapy 1987; 7: 211–5PubMedGoogle Scholar
  63. 63.
    Townsend RJ, Benedetti TJ, Erickson SH, et al. Excretion of ibuprofen into breast milk. Am J Obstet Gynecol 1984; 149: 184–6PubMedGoogle Scholar
  64. 64.
    Weibert RT, Townsend RJ, Kaiser DG, et al. Lack of ibuprofen secretion into humanmilk. Clin Pharm 1982; 1: 457–8PubMedGoogle Scholar
  65. 65.
    Walter K, Dilger C. Ibuprofen in human milk. Br J Clin Pharmacol 1997; 44: 211–2PubMedGoogle Scholar
  66. 66.
    Lebedevs TH, Wojnar-Horton RE, Yapp P, et al. Excretion of indomethacin in breast milk. J Clin Pharmacol 1991; 32: 751–4Google Scholar
  67. 67.
    Wischnik A, Manth SM, Lloyd J, et al. The excretion of ketorolac tromethamine into breast milk after multiple oral dosing. Eur J Clin Pharmacol 1989; 36: 521–4PubMedCrossRefGoogle Scholar
  68. 68.
    Huber R, Zech K, Dittmann EC, et al. Pharmacokinetics of the antirheumatic lonazolac-Ca in humans [in German]. Arzneimittelforschung 1990; 40: 918–25PubMedGoogle Scholar
  69. 69.
    Buchanan RA, Eaton CJ, Koeff ST, et al. The breast milk excretion of mefenamic acid. Curr Ther Res Clin Exp 1968; 10: 592–7PubMedGoogle Scholar
  70. 70.
    Jamali F, Stevens DR. Naproxen excretion in milk and its uptake by the infant. Drug Intell Clin Pharm 1983; 17: 910–1PubMedGoogle Scholar
  71. 71.
    Brogden RN, Pinder RM, Sawyer PR, et al. Naproxen: a review of its pharmacological properties and therapeutic efficacy and use. Drugs 1975; 9: 326–63PubMedCrossRefGoogle Scholar
  72. 72.
    Östensen M, Matheson I, Laufen H. Piroxicam in breast milk after long-term treatment. Eur J Clin Pharmacol 1988; 35: 567–9PubMedCrossRefGoogle Scholar
  73. 73.
    Östensen M. Piroxicam in human breast milk. Eur J Clin Pharmacol 1983; 25: 829–30PubMedCrossRefGoogle Scholar
  74. 74.
    Knowles JA. Excretion of drugs in milk: a review. J Pediatr 1965; 66: 1068–82PubMedCrossRefGoogle Scholar
  75. 75.
    Heintz RC, Stebler T, Lunell O, et al. Excretion of tenoxicam and 5-hydroxy-tenoxicam into human milk. J Pharm Med 1993; 3: 57–64Google Scholar
  76. 76.
    Sagraves R, Waller ES, Goehrs HR. Tolmetin in breast milk. Drug Intell ClinPharm 1985; 19: 55–6Google Scholar
  77. 77.
    Goldsmith DP. Neonatal rheumatic disorders: view of the pediatrician. Rheum Dis Clin North Am 1989; 15: 287–305PubMedGoogle Scholar
  78. 78.
    Rizzoni G, Furlanut M. Cyanotic crises in a breast-fed infant from mother taking dipyrone. Hum Toxicol 1984; 3: 505–7PubMedCrossRefGoogle Scholar
  79. 79.
    Eeg-Olofsson O, Malmros I, Elwin CE, et al. Convulsions in a breast-fed infant after maternal indomethacin [letter]. Lancet 1978; II: 215CrossRefGoogle Scholar
  80. 80.
    Fairhead FW. Convulsions in a breast-fed infant after maternal indomethacin [letter]. Lancet 1978; II: 576CrossRefGoogle Scholar
  81. 81.
    Fidalgo I, Correa R, Gomez-Carrasco JA, et al. Anemia aguda, rectorragia y hematuria asociadas a la ingestion de naproxen. An Esp Pediatr 1989; 30: 317–9PubMedGoogle Scholar
  82. 82.
    Pittman KA, Smyth RD, Losada M, et al. Human perinatal distribution of butorphanol. Am J Obstet Gynecol 1980; 138: 797–800PubMedGoogle Scholar
  83. 83.
    Meny RG, Naumburg EC, Alger LS, et al. Codeine and the breastfed neonate. J Hum Lact 1993; 9: 237–40PubMedCrossRefGoogle Scholar
  84. 84.
    Steer PL, Biddle CJ, Marley WS, et al. Concentration of fentanyl in colostrum after ananalgesic dose. Can J Anesth 1992; 39: 231–5PubMedCrossRefGoogle Scholar
  85. 85.
    Leuschen MP, Wolf LJ, Rayburn WF. Fentanyl excretion in breast milk. Clin Pharm 1990: 9: 336–7PubMedGoogle Scholar
  86. 86.
    Gerdin E, Bondesson U, Hartvig P. Excretion of ketobemidone in human breast milk. J Perinat Med 1996; 24: 293–5PubMedCrossRefGoogle Scholar
  87. 87.
    Feilberg VL, Rosenborg D, Christensen CB, et al. Excretion of morphine in human breast milk. Acta Anaesthesiol Scand 1989; 33: 426–8PubMedCrossRefGoogle Scholar
  88. 88.
    Wittels B, Scott DT, Sinatra RS. Exogenous opioids in human breast milk and acute neonatal neurobehavior: a preliminary study. Anesthesiology 1990; 73: 864–9PubMedCrossRefGoogle Scholar
  89. 89.
    Peiker G, Müller B, Ihn W, et al. Ausscheidung von Pethidin durch die Muttermilch. Zbl Gynaekol 1980: 102: 537–41Google Scholar
  90. 90.
    Quinn PG, Kuhnert BR, Kaine CJ, et al. Measurement of meperidine and normeperidine in human breast milk by selected ion monitoring. Biomed Environ Mass Spectrom 1986; 13: 133–5PubMedCrossRefGoogle Scholar
  91. 91.
    Borgatta L, Jenny RW, Gruss L, et al. Clinical significance of methohexital, meperidine, and diazepam in breast milk. J Clin Pharmacol 1997; 37: 186–92PubMedGoogle Scholar
  92. 92.
    Kunka RL, Venkataramanan R, Stern RM, et al. Excretion of propoxyphene and norpropoxyphene in breast milk. Clin Pharmacol Ther 1984; 35: 675–80PubMedCrossRefGoogle Scholar
  93. 93.
    Kunka RL, Yong C-L, Ladik CF, et al. Liquid chromatographic determination of propoxyphene and norpropoxyphene in plasma and breast milk. J Pharm Sci 1985; 74: 103–4PubMedCrossRefGoogle Scholar
  94. 94.
    Robieux I, Koren G, Vandenbergh H, et al. Morphine excretion in breast milk and resultant exposure of a nursing infant. J Toxicol Clin Toxicol 1990; 28: 365–70PubMedCrossRefGoogle Scholar
  95. 95.
    Sindrup SH, Brösen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5: 335–46PubMedCrossRefGoogle Scholar
  96. 96.
    Lynn AM, Opheim KE, Tyler DC. Morphine infusion after pediatric cardiac surgery. Crit Care Med 1984; 12: 863–6PubMedCrossRefGoogle Scholar
  97. 97.
    Olkkola KT, Maunuksela EL, Korpela R, et al. Kinetics and dynamics of postoperative intravenous morphine in children. Clin Pharmacol Ther 1988; 44: 128–36PubMedCrossRefGoogle Scholar
  98. 98.
    Terwilliger WG, Hatcher RA. The elimination of morphine and quinine in human milk. Surg Gynecol Obstet 1934; 58: 823–6Google Scholar
  99. 99.
    Wittels B, Glosten B, Faure EAM, et al. Postcesarean analgesia with both epidural morphine and intravenous patient-controlled analgesia: neurobehavioral outcomes among nursing neonates. Anesth Analg 1997; 85: 600–6PubMedGoogle Scholar
  100. 100.
    Koren G, Levy M. Opioid uses in children. Pediatr Clin North Am 1989; 36: 1141–55PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Department of Clinical PharmacologyRegional and University HospitalTrondheimNorway
  2. 2.Division of Clinical PharmacologyNorrland University HospitalUmeåSweden

Personalised recommendations